【摘要】 目的观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法 2007年1月至2009年2月我科收治的急性脑梗死患者14例,给予0.9%生理盐水100ml+尤瑞克林0.15PNA静脉滴注,每天1次,连续治疗7～14d。治疗期间针对性地给予抗血小板制剂(Aspirin100mg/d)以及其他常规治疗。结果 14例患者治疗7～14d后,平均NIHSS评分及ADL评分均较治疗前明显降低(P<0.05),临床疗效显著,总有效率达71.42%。结论尤瑞克林治疗急性重型缺血性脑卒中安全、有效,未发现明显副作用,值得临床推广使用。更多还原

【Abstract】 Objective The efficacy and safety of Urinary Kallidinogenase in treating patients with acute cerebral infarction have been observed. Methods The therapeutic effect and adverse effect were analyzed in 14 cases of acute cerebral infarction who underwent intravenous injection of Urinary Kallidinogenase 0.15 PNA qd in the ICU of the second affiliated Hospital of Dalian Medical University,from January 2007 to February 2009.The patients have been evaluated by NIHSS and ADL at 7-14 days after initiating the therapy. Results A significant improvement in NIHSS and ADL scores of these patients was noted. And 71.42% of them obtained satisfactory improvement. Conclusions Kallidinogenase injection showed a relatively confirmative effect on the improvement of cerebral functions in patients with acute cerebral infarction. The adverse effects were minimal. However,the exact efficacy needs further RCT clinical trials.更多还原